Belzutifan

CHEMBL4585668 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
383.3 g/mol
LogP
2.0
Phase
4

A HIF-2 alpha inhibitor that blocks the transcription factor driving the growth of certain kidney cancers and tumors associated with von Hippel-Lindau disease. It reduces the expression of growth factors that tumors need for angiogenesis.

Berat Molekul

383,3000 g/mol

LogP

2,00

TPSA

95,80 Ų

Lipinski RO5

Lulus

Area Terapeutik

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F

InChI

InChI=1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1

Molecular Formula

C17H12F3NO4S

HBD / HBA

1 / 8

Ikatan yang Dapat Dirotasi

3

Atom Berat

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A HIF-2 alpha inhibitor that blocks the transcription factor driving the growth of certain kidney cancers and tumors associated with von Hippel-Lindau disease. It reduces the expression of growth factors that tumors need for angiogenesis.

Yes, Belzutifan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4585668. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 117947097. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.